ID
17651
Beschrijving
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part: Moisturizers and Sunscreens
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Trefwoorden
Versies (2)
- 01-08-16 01-08-16 -
- 27-09-16 27-09-16 -
Geüploaded op
27 september 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Moisturizers and Sunscreens, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Moisturizers and Sunscreens, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Similar models
Moisturizers and Sunscreens, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0038818 (UMLS CUI [2])
C0038818 (UMLS CUI [2])
C0808070 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0808070 (UMLS CUI [2,2])
C0808070 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0808070 (UMLS CUI [2,2])
C0806020 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0806020 (UMLS CUI [2,2])
C0806020 (UMLS CUI [1,2])
C0038818 (UMLS CUI [2,1])
C0806020 (UMLS CUI [2,2])